#Osimeritinib
Explore tagged Tumblr posts
Visit Tumblr Blog
Explore Tumblr blogs with no restrictions, modern design and the best experience.
Last Seen Tumblr Blogs
Fun Fact
Hackers stole 65M passwords from Tumblr in 2013.
Text
TAGRISSO 40MG [OSIMERITINIB 40MG]
DESCRIPTION
Tagrisso 40mg
A Tagrisso 40mg tablet is containing an active substance known as Osimeritinib, which is formerly known as Mereletinib.
Tagrisso 40mg is considered as third generation medicine, which is available in tablet form.
Tagrisso 40mg is an inevitable, selectively deviated epidermal growth factor receptor prohibitor, containing anti-cancer activity.
The pharmacological category of Tagrisso 40mg is tyrosine kinase prohibitor.
INDICATION
Tagrisso 40mg
A Tagrisso 40mg tablet is widely indicated as first line therapy for advanced non-small cell lung cancer with EGFR mutation positive patients.
Tagrisso 40mg is also used for the treatment of patients affected with advanced EGFR T792M mutation positive NSCLC, disease has advanced on or after the tyrosine kinase inhibitor treatment.
MECHANISM OF ACTION
Tagrisso 40mg
Osimeritinib is similar in action when compared to other tyrosine kinase inhibitor drugs.
Osimeritinib is named tyrosine kinase inhibitor of epidermal development factor receptor which is available on the surface of tumor cells
Osimeritinib is non-reversibly converge with mutant type of EGFR at 9 folds than wild sort
Forbids EGFR sharpening changes exon 19 Del and L858R
Prompts denies transformed EGFR with T790M opposition transformation
At last, bring down action against wild kind EGFR
Tagrisso 40mg
PROPERTIES
Ingredients : Osimeritinib
Strength : 40mg
Package : 30 tablets in a carton
ADME
Absorption :
High plasma concentration time of Osimeritinib reaches within 6 hours
Distribution :
Volume of distribution 918L
Human Plasma protein bound to Osimeritinib is 95%
Metabolism :
The metabolism of Osimeritinib is occurs via oxidation.
The Two pharmacologically active metabolite of Osimeritinib are AZ7550 & AZ5104
Excretion :
The mean terminal half-life period 48 hours
Clearance value 14.3L/hr
68% of metabolite is excreted in feces; 14% through urine
2% of unchanged form of drug is eliminated
DOSAGE MANAGEMENT
The recommended dosage of Tagrisso tablet are, 80mg tablet should be taken as a single dose.
Tagrisso 40mg tablet should be administered with or without food.
If patient felt difficult to swallow the Tagrisso tablets as such, must disperse the tablet in 60ml of noncarbonated water and drink the solution immediately.
Tagrisso tablet do not break, crush or chew.
Interrupt the treatment during the conditions like;
Interstitial lung disease
QT prolongation
Symptomatic congestive heart failure
In pain management
Grade III or severe: discontinue the Tagrisso 40mg tablet for 3 weeks
Grade 0 to II: follow at 80mg or 40mg as a single dose
If no development in 3 weeks: Discontinue the therapy.
While co administration of Tagrisso with CYP3A4 inducers, the dosage of Tagrisso should be increased to 160mg as a single dose and followed by 80mg for 3 weeks after discontinuation of strong CYP3A4 inducers.
PRECAUTIONS
nterstitial lung disease:
To avoid this problem, withheld or stop the Tagrisso 40mg tablets.
Keratitis:
check the manifestation of keratitis regularly and provide supportive measures
Embryo fetal toxicity:
Tagrisso 40mg tablet required in pregnancy period causes fetal damage.
QTc extension:
Do not concurrent use of Tagrisso 40mg with drug prolong the QTc
Cardiomyopathy:
Periodic cardiac monitoring is assessed; in this condition stop the therapy.
SIDE EFFECTS
Tagrisso 40mg
The most common adverse effects occurred during the therapy;
Cardiomyopathy, QT prolongation, Interstitial lung disease, Keratitis.
Other common side effect :
Tagrisso 40mg
Diarrhea or constipation, Hyperglycemia, Hypomagnesemia, Hyponatremia, Elevation of AST & ALT, Stomatitis, Nausea, Vomiting, Rash, Nail toxicity, Pruritus, Dry skin, Headache, Cough, Dyspnea, Fatigue, Pyrexia, Loss of appetite, Respiratory tract infection, Lymphopenia,Thrombocytopenia, Anemia, Neutropenia.
PREGNANCY
Pregnancy category of Osimeritinib is not designate
While using Tagrisso 40mg tablet causes possible for fetal harm
LACTATION
Milk feeding should not be taken during lactation period.
STORAGE
The Tagrisso 40mg tablet is, stored at 25°C.
Keep the tablet carton from moisture, heat and light.
MISSED DOSE
In case of missed dose, do not take the missed dose and follow the regular dosing schedule.
CONTACT US
PHONE NO: +91-9940472902
EMAIL: [email protected]
WEBSITE: https://millionpharma.com/osimeritinib-40mg.php
1 note
·
View note
Text
TAGRISSO 80MG|OSIMERITINIB 80MG|MHP
DESCRIPTION
Tagrisso 80mg
A Tagrisso 80mg tablet is containing an active substance known as Osimeritinib, which is formerly known as Mereletinib.
Tagrisso 80mg is considered as third generation medicine, which is available in tablet form.
Tagrisso 80mg is an inevitable, selectively deviated epidermal growth factor receptor prohibitor, containing anti-cancer activity.
The pharmacological category of Tagrisso 80mg tablet is tyrosine kinase prohibitor.
INDICATION
Tagrisso 80mg
A Tagrisso 80mg tablet is widely indicated as first line therapy for advanced non-small cell lung cancer with EGFR mutation positive patients.
Tagrisso 80mg tablet is also used for the treatment of patients affected with advanced EGFR T792M mutation positive NSCLC, disease has advanced on or after the tyrosine kinase inhibitor treatment.
MECHANISM OF ACTION
Tagrisso 80mg
PROPERTIES
Ingredients : Bevacizumab
Strength : 100mg/4ml
Package : 400mg of Bevacizumab containing vial
ADME PROPERTIES
Absorption :
High plasma concentration time of Osimeritinib reaches within 6 hours
Distribution :
Volume of distribution 918L
Human Plasma protein bound to Osimeritinib is 95%
Metabolism :
The metabolism of Osimeritinib is occurs via oxidation.
The Two pharmacologically active metabolite of Osimeritinib are AZ7550 & AZ5104
Excretion :
The mean terminal half-life period 48 hours
Clearance value 14.3L/hr
68% of metabolite is excreted in feces; 14% through urine
2% of unchanged form of drug is eliminated
DOSAGE MANAGEMENT
The recommended dosage of Tagrisso 80mg tablets are, 80mg tablet should be taken as a single dose.
Tagrisso tablet should be administered with or without food.
If patient felt difficult to swallow the Tagrisso tablets as such, must disperse the tablet in 60ml of noncarbonated water and drink the solution immediately.
Tagrisso tablet do not break, crush or chew.
Interrupt the treatment during the conditions like;
Interstitial lung disease
QT prolongation
Symptomatic congestive heart failure
In pain management
Grade III or severe: discontinue the Tagrisso tablet for 3 weeks
Grade 0 to II: follow at 80mg or 40mg as a single dose
If no development in 3 weeks: Discontinue the therapy.
While co administration of Tagrisso with CYP3A4 inducers, the dosage of Tagrisso 80mg should be increased to 160mg as a single dose and followed by 80mg for 3 weeks after discontinuation of strong CYP3A4 inducers.
PRECAUTIONS
Interstitial lung disease:
Tagrisso 80mg
To avoid this problem, withheld or stop the Tagrisso 80mg tablets.
Keratitis:
Tagrisso 80mg
check the manifestation of keratitis regularly and provide supportive measures
Embryo fetal toxicity:
Tagrisso 80mg
Tagrisso 80mg tablet required in pregnancy period causes fetal damage.
QTc extension:
Do not concurrent use of Tagrisso 80mg with drug prolong the QTc
Cardiomyopathy:
Tagrisso 80mg
Periodic cardiac monitoring is assessed; in this condition stop the therapy.
SIDE EFFECTS
The most common adverse effects occurred during the therapy;
Cardiomyopathy, QT prolongation, Interstitial lung disease, Keratitis.
Other common side effect :
Diarrhea or constipation, Hyperglycemia, Hypomagnesemia, Hyponatremia, Elevation of AST & ALT, Stomatitis, Nausea, Vomiting, Rash, Nail toxicity, Pruritus, Dry skin, Headache, Cough, Dyspnea, Fatigue, Pyrexia, Loss of appetite, Respiratory tract infection, Lymphopenia, Thrombocytopenia, Anemia, Neutropenia.
PREGNANCY
Pregnancy category of Osimeritinib is not designate
While using Tagrisso 80mg tablet causes possible for fetal harm.
LACTATION
Milk feeding should not be taken during lactation period.
STORAGE
The Tagrisso 80mg tablet is, stored at 25°C.
Keep the tablet carton from moisture, heat and light.
MISSED DOSE
In case of missed dose, do not take the missed dose and follow the regular dosing schedule.
CONTACT US
PHONE NO:+91-9940472902 EMAIL :[email protected] WEBSITE :
https://millionpharma.com/osimeritinib-80mg.php
1 note
·
View note
Text
OSIMERITINIB 40MG
DESCRIPTION
A Tagrisso 40mg tablet is containing an active substance known as Osimeritinib, which is formerly known as Mereletinib. Tagrisso 40mg is considered as third generation medicine, which is available in tablet form. Tagrisso 40mg is an inevitable, selectively deviated epidermal growth factor receptor prohibitor, containing anti-cancer activity. The pharmacological category of Tagrisso 40mg is tyrosine kinase prohibitor.
INDICATION
A Tagrisso 40mg tablet is widely indicated as first line therapy for advanced non-small cell lung cancer with EGFR mutation positive patients. Tagrisso 40mg is also used for the treatment of patients affected with advanced EGFR T792M mutation positive NSCLC, disease has advanced on or after the tyrosine kinase inhibitor treatment.
MECHANISM OF ACTION
Osimeritinib is similar in action when compared to other tyrosine kinase inhibitor drugs. Osimeritinib, Tagrisso 40mg tablet is named tyrosine kinase inhibitor of epidermal development factor receptor which is available on the surface of tumor cells Osimeritinib is non-reversibly converge with mutant type of EGFR at 9 folds than wild sort Forbids EGFR sharpening changes exon 19 Del and L858R Prompts denies transformed EGFR with T790M opposition transformation. At last, bring down action against wild kind EGFR
ADME
Absorption :High plasma concentration time of Osimeritinib reaches within 6 hours
Distribution :Volume of distribution 918LHuman Plasma protein bound to Osimeritinib is 95%
Metabolism :The metabolism of Osimeritinib is occurs via oxidation.The Two pharmacologically active metabolite of Osimeritinib are AZ7550 & AZ5104
Excretion : The mean terminal half-life period 48 hours Clearance value 14.3L/hr 68% of metabolite is excreted in feces; 14% through urine 2% of unchanged form of drug is eliminated
DOSAGE MANAGEMENT
The recommended dosage of the tablets are, 80mg tablet should be taken as a single dose. Tagrisso 40mg tablet should be administered with or without food.If patient felt difficult to swallow the Tagrisso 40mg tablets as such, must disperse the tablet in 60ml of noncarbonated water and drink the solution immediately. Tagrisso 40mg tablet do not break, crush or chew. Interrupt the treatment during the conditions like; Interstitial lung disease QT prolongation Symptomatic congestive heart failure In pain management Grade III or severe: discontinue the Tagrisso 40mg tablet for 3 weeks Grade 0 to II: follow at 80mg or 40mg as a single dose If no development in 3 weeks: Discontinue the therapy. While co administration of Tagrisso 40mg with CYP3A4 inducers, the dosage of Tagrisso 40mg should be increased to 160mg as a single dose and followed by 80mg for 3 weeks after discontinuation of strong CYP3A4 inducers.
PRECAUTION
SInterstitial lung disease: To avoid this problem, withheld or stop the Tagrisso 40mg tablets. Keratitis: check the manifestation of keratitis regularly and provide supportive measures Embryo fetal toxicity: Tagrisso 40mg tablet required in pregnancy period causes fetal damage. QTc extension: Do not concurrent use of Tagrisso 40mg with drug prolong the QTc Cardiomyopathy: Periodic cardiac monitoring is assessed; in this condition stop the therapy.
SIDE EFFECTS
The most common adverse effects occurred during the therapy; Cardiomyopathy, QT prolongation, Interstitial lung disease, Keratitis. Other common side effect : Diarrhea or constipation, Hyperglycemia, Hypomagnesemia, Hyponatremia, Elevation of AST & ALT, Stomatitis, Nausea, Vomiting, Rash, Nail toxicity, Pruritus, Dry skin, Headache, Cough, Dyspnea, Fatigue, Pyrexia, Loss of appetite, Respiratory tract infection, Lymphopenia, Thrombocytopenia, Anemia, Neutropenia.
PREGNANCY
Pregnancy category of Osimeritinib is not designate While using Tagrisso 40mg tablet causes possible for fetal harm
LACTATION
Milk feeding should not be taken during lactation period.
STORAGE
The Tagrisso 40mg tablet is, stored at 25°C. Keep the tablet carton from moisture, heat and light.
MISSED DOSE
In case of missed dose, do not take the missed dose and follow the regular dosing schedule.
CONTACT US
MAIL ID : [email protected]
PHONE NO : +91-9940472902
WEBSITE : https://millionpharma.com/osimeritinib-40mg.php
0 notes